The resolution rate of Enhertu's treatment of patients with brain metastases of HER2-positive breast cancer reached 73.3%! 29/11/2023
ER+/HER2-monotherapy for breast cancer! Elacestrant applies for listing in the United States 15/12/2022
The FDA approved the new indication of Enhertu! The first targeted therapy for HER2 low-expression breast cancer is available 17/11/2022
Daiichi Sankyo submits a listing application for a new indication of Enhertu for the treatment of HER2 low-expression breast cancer in Japan 16/11/2022
Trodelvy is approved for the second-line treatment of metastatic triple-negative breast cancer 08/11/2022
Breast cancer cells may change their identity and become more aggressive 21/06/2022 breast cancer EMT gene
Precision treatment of triple-negative breast cancer | Gosatuzumab research data –HKUOC 21/06/2022 breast cancer
